Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024
April 08, 2024 08:00 ET
|
Syncromune
Initial clinical data demonstrate a very high 85% overall response rate in patients with metastatic castrate-resistant prostate cancer. FORT LAUDERDALE, Fla., April 08, 2024 (GLOBE NEWSWIRE) --...
Syncromune® Inc. to Present Initial Clinical Data from SYNC-T™ SV-102 Phase 1 as a Late-Breaker at the American Association for Cancer Research Annual Meeting 2024
March 06, 2024 08:00 ET
|
Syncromune
FORT LAUDERDALE, Fla., March 06, 2024 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, an in situ platform combination...